Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for arterial wall inflammation in statin-intolerant high cardiovascular risk patients
NL-OMON20315Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in hypercholesterolemia and cardiac morbidity comparing Alirocumab with Placebo (2 arms). Primary endpoint: Change in 18F-FDG target-to-background ratio. Started May 2017; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on NL-OMON20315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20315.